What is Draxxin Used For in Cattle?

Draxxin, a powerful and versatile antimicrobial, plays a crucial role in modern cattle health management. Primarily utilized for its efficacy against a broad spectrum of bacterial pathogens, Draxxin is a go-to treatment for respiratory diseases and foot rot in beef and dairy cattle. Its long-acting formulation provides sustained therapeutic levels, simplifying treatment regimens and ensuring consistent protection. Understanding its applications, mechanisms of action, and proper usage is paramount for veterinarians and producers seeking to maintain herd health and productivity.

Table of Contents

Understanding Draxxin and its Active Ingredient

Draxxin is the brand name for tulathromycin, a semi-synthetic macrolide antibiotic. Macrolides are a class of antibiotics characterized by a large macrocyclic lactone ring to which one or more deoxy sugars may be attached. This unique structure allows macrolides to bind to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis, which is essential for bacterial survival and replication.

The broad spectrum of activity of tulathromycin is a key reason for its widespread use. It is effective against many Gram-positive bacteria and a significant number of Gram-negative bacteria, including those commonly implicated in bovine respiratory disease (BRD) and foot rot. Key pathogens targeted by Draxxin include:

Mannheimia haemolytica: A primary causative agent of BRD.
Pasteurella multocida: Another significant contributor to BRD.
Histophilus somni: Often associated with BRD and reproductive issues.
Mycoplasma bovis: A notoriously difficult-to-treat pathogen that causes BRD and mastitis.
Fusobacterium necrophorum: A major bacterium involved in the development of bovine foot rot (interdigital necrobacillosis).
Porphyromonas levii: Also commonly found in cases of foot rot.

The pharmacokinetic profile of Draxxin is another significant advantage. Once administered, tulathromycin is rapidly absorbed and distributed throughout the body, reaching high concentrations in lung tissues, which are often the primary site of infection in BRD. Its extended half-life means that a single injection can provide therapeutic coverage for a prolonged period, typically up to 14 days, reducing the need for repeated treatments. This sustained release is a hallmark of macrolide antibiotics and contributes to improved treatment outcomes and reduced animal stress.

Mechanism of Action

The mechanism by which Draxxin exerts its antibacterial effect is through the inhibition of protein synthesis. Bacteria, like all living organisms, rely on the synthesis of proteins to carry out essential cellular functions. This process occurs within ribosomes, complex molecular machines composed of ribosomal RNA and proteins.

Tulathromycin, as a macrolide, binds to the 50S ribosomal subunit. Specifically, it binds to the P-site of the 23S ribosomal RNA component. This binding interferes with the translocation step of protein synthesis, where the ribosome moves along the messenger RNA (mRNA) molecule to read the next codon. By preventing this movement, the elongation of the polypeptide chain is halted, and bacteria are unable to produce the proteins necessary for their growth, repair, and reproduction.

The bacteriostatic nature of macrolides, including tulathromycin, means that they inhibit bacterial growth rather than directly killing the bacteria. However, at higher concentrations or in combination with the host’s immune system, they can exhibit bactericidal activity against certain susceptible organisms. The host’s immune system then clears the inhibited or weakened bacteria. This mechanism is particularly beneficial in treating chronic or difficult infections, as it allows the immune system time to mount an effective response.

Primary Uses of Draxxin in Cattle

Draxxin’s efficacy against a wide range of bacterial pathogens makes it an indispensable tool in managing two of the most common and economically significant disease complexes in cattle: Bovine Respiratory Disease (BRD) and foot rot.

Bovine Respiratory Disease (BRD)

Bovine Respiratory Disease, often referred to as “shipping fever,” is a complex syndrome resulting from the interaction of environmental stressors, viral infections, and bacterial infections. It is the leading cause of mortality and morbidity in feedlot cattle and a significant concern in stocker and cow-calf operations. BRD can manifest in various forms, from mild coughing and nasal discharge to severe pneumonia leading to rapid deterioration and death.

Draxxin is a critical component of BRD treatment protocols due to its effectiveness against the primary bacterial pathogens involved. It is frequently used for:

Treatment of established BRD cases: When cattle exhibit clinical signs of BRD, such as fever, lethargy, anorexia, nasal discharge, and coughing, Draxxin is often administered as a therapeutic treatment. Its broad spectrum and long-acting properties make it suitable for treating animals that may be stressed or have compromised immune systems. The ability to provide a single injection that lasts for an extended period simplifies treatment and reduces handling stress on sick animals.
Metaphylactic treatment: In situations where BRD risk is high, such as upon arrival at a feedlot or during periods of extreme weather, Draxxin can be used for metaphylaxis. This involves treating an entire group of animals, even those not yet showing clinical signs, to prevent or minimize the incidence of disease. This strategy is particularly effective when the prevalence of BRD within a group is anticipated to be high. By treating the entire group, Draxxin helps to reduce the bacterial load in the environment and prevent the spread of infection among susceptible animals, thereby lowering the overall morbidity and mortality rates.
Prevention of BRD in high-risk calves: Calves undergoing weaning, transport, or commingling are particularly susceptible to BRD. A single dose of Draxxin administered at these times can provide a critical buffer against the onset of respiratory illness, allowing the calves to adapt to new environments and diets more effectively.

The success of Draxxin in BRD management is attributed to its ability to reach high concentrations in lung tissue, the primary site of infection. This localized high concentration of the antibiotic is crucial for eradicating the bacterial pathogens causing pneumonia.

Foot Rot (Interdigital Necrobacillosis)

Foot rot is a highly contagious and painful bacterial infection affecting the interdigital space of cattle. It is characterized by lameness, swelling, and ulceration of the skin between the claws. The condition is often exacerbated by wet, muddy conditions, which can macerate the skin, allowing opportunistic bacteria to invade.

Draxxin is highly effective in treating foot rot due to its activity against Fusobacterium necrophorum and Porphyromonas levii, the main bacterial culprits.

Treatment of clinical foot rot: When cattle present with lameness and visible lesions characteristic of foot rot, Draxxin provides rapid and effective treatment. The antibiotic helps to control the bacterial infection, reduce inflammation, and alleviate pain, allowing for quicker recovery and return to normal locomotion.
Prevention in outbreak situations: In herds or pens where foot rot is prevalent or has recently occurred, Draxxin can be used to prevent further spread of the infection. Treating animals exposed to the causative bacteria can help to prevent the development of clinical signs.

The convenience of a single, long-acting injection simplifies the treatment of foot rot, especially in large herds where individual hoof care can be labor-intensive and stressful for the animals. By addressing the bacterial infection systemically, Draxxin helps to resolve the lesions and restore mobility.

Administration and Dosage Guidelines

Proper administration and adherence to dosage guidelines are critical to maximizing the efficacy of Draxxin and ensuring animal safety. As an injectable antibiotic, Draxxin should only be administered by or on the order of a licensed veterinarian.

Injection Site and Technique

Draxxin is administered subcutaneously (SC) – under the skin. The preferred injection site is in the neck, in front of or behind the shoulder, in the region of the cervical muscles. This location offers several advantages:

Reduced risk of carcass damage: Injecting in the neck minimizes contamination of valuable meat cuts, which is a major concern in beef cattle.
Good tissue penetration: The musculature in the neck allows for adequate absorption of the drug.
Ease of restraint: Cattle are typically easier to restrain safely for neck injections.

Key administration techniques to follow:

Cleanliness: Ensure the injection site is clean and dry. Wipe the area with an antiseptic wipe to reduce the risk of introducing skin bacteria into the injection site.
Needle selection: Use a clean, sharp, appropriately sized needle. A 16-gauge needle, 1-inch or 1.5-inch in length, is typically recommended. Dull or bent needles can cause pain, tissue damage, and poor drug delivery.
Dose measurement: Accurately measure the required dose of Draxxin using a calibrated syringe.
Injection technique:
- Grasp a fold of skin at the chosen injection site.
- Insert the needle through the skin and into the subcutaneous space. Do not inject into the muscle.
- Administer the full dose slowly and steadily.
- Withdraw the needle smoothly and apply gentle pressure to the injection site to help prevent leakage.
Rotation of sites: If multiple injections are required for the same animal or group, rotate the injection sites to prevent local tissue reactions and ensure proper absorption.

Dosage and Duration of Therapy

The recommended dosage of Draxxin is 2.5 mg of tulathromycin per kilogram of body weight (1.14 mg per pound). This translates to 1 mL of Draxxin per 40 kg (88 lb) of body weight.

Example:

A calf weighing 200 kg (440 lb) would require a dose of 5 mL (200 kg / 40 kg/mL).
A cow weighing 400 kg (880 lb) would require a dose of 10 mL (400 kg / 40 kg/mL).

It is crucial to weigh cattle to determine accurate dosages. Over- or under-dosing can lead to treatment failure or the development of antibiotic resistance.

The extended-acting nature of Draxxin means that a single subcutaneous injection is typically sufficient to treat BRD and foot rot. The drug maintains therapeutic concentrations for up to 14 days, providing prolonged protection and reducing the need for repeat treatments.

Withdrawal Periods

As with all veterinary pharmaceuticals, Draxxin has established withdrawal periods. These are the periods between the last administration of the drug and when the animal can be slaughtered for human consumption or its milk can be used. These periods are legally mandated to ensure that drug residues in meat and milk are below acceptable safety limits.

Beef Cattle: The withdrawal period for Draxxin in beef cattle is 18 days.
Non-Lactating Dairy Cattle: The withdrawal period for Draxxin in non-lactating dairy cattle is 22 days.
Lactating Dairy Cattle: Draxxin is not approved for use in lactating dairy cattle.

Producers must meticulously record all drug administrations, including the drug name, dosage, date of administration, and animal identification, to ensure compliance with withdrawal periods. Failure to adhere to these periods can result in condemnation of carcasses or milk, leading to significant economic losses and public health concerns.

Considerations for Responsible Use and Resistance

The judicious and responsible use of antibiotics like Draxxin is paramount to preserving their effectiveness for future generations of cattle and humans. The emergence of antimicrobial resistance (AMR) is a global health challenge, and the veterinary community plays a vital role in mitigating its spread.

Preventing Antimicrobial Resistance

Antimicrobial resistance occurs when bacteria evolve and become less susceptible to the effects of antibiotics. This can happen when antibiotics are used unnecessarily, at incorrect doses, or for insufficient durations, allowing partially resistant bacteria to survive and multiply. To combat AMR, several principles of responsible antibiotic use should be followed:

Diagnosis-driven treatment: Draxxin should be used based on a diagnosis or strong suspicion of a bacterial infection that it is known to treat. This means veterinary involvement is essential to confirm the presence of bacterial disease and rule out other causes of illness.
Appropriate use for labeled indications: Use Draxxin strictly for the indications for which it is approved: treatment of BRD and foot rot. Off-label use should be carefully considered and only undertaken under veterinary supervision.
Correct dosage and duration: Always administer the correct dose and ensure that the single-injection regimen is appropriate for the condition being treated. Do not shorten or extend the duration of therapy without veterinary guidance.
Hygiene and biosecurity: Good farm management practices, including proper sanitation, ventilation, and biosecurity measures, can significantly reduce the incidence of disease, thereby decreasing the need for antibiotics.
Vaccination programs: Implementing comprehensive vaccination programs against common viral and bacterial pathogens that contribute to BRD can bolster the immune system of cattle and reduce their susceptibility to bacterial infections.

The Role of Veterinary Oversight

Veterinarians are central to the responsible use of Draxxin. They are trained to:

Accurately diagnose diseases and determine if bacterial infection is present.
Select the most appropriate antibiotic for a given situation, considering the pathogen, the animal, and potential resistance patterns.
Educate producers on proper administration techniques, withdrawal periods, and biosecurity measures.
Monitor herd health and identify trends that may indicate emerging resistance or areas for improved management.

By working closely with veterinarians, cattle producers can ensure that Draxxin is used as an effective tool for maintaining animal health and welfare while simultaneously contributing to the global effort to combat antimicrobial resistance. This collaborative approach safeguards the longevity of vital antimicrobial therapies for both animal and human health.